Literature DB >> 6253707

Serum levels of fibronectin and a fibronectin-like DNA-binding protein in patients with various diseases.

H D Todd, M S Coffee, T P Waalkes, M D Abeloff, R G Parsons.   

Abstract

The levels of fibronectin and the fibronectin-like, malignant disease-associated DNA-binding protein (MAD-2) were determined in sera from patients with various diseases. The levels of both proteins were elevated in most serum samples from patients with various types of cancer and in some patients with nonmalignant diseases. The highest levels of these proteins were found in patients with carcinomas of the breast and lung. A subset of the lung cancer patients with small cell carcinoma had either normal or depressed marker levels. The levels of fibronectin and MAD-2 varied concordantly in the different patient populations studied, which suggests that the serum levels of the fragment are directly proportional to the total amount of fibronectin in the serum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253707

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Elevated plasma fibronectin levels in nephrotic syndrome.

Authors:  J Zazgornik; W Graninger; E Minar; P Schmidt; P Balcke; A Haubenstock; H Kopsa
Journal:  Klin Wochenschr       Date:  1984-06-01

2.  Pattern of fibronectin distribution in human lung cancer.

Authors:  H Nagai; M Isemura; H Arai; T Abe; S Shimoda; M Motomiya; H Sato; K Hashimoto; K Takusagawa; K Konno
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Plasma fibronectin in psoriatic arthritis subgroups.

Authors:  M Cutolo; S Accardo; M A Cimmino; S Rovida
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

4.  [Fibronectin].

Authors:  E Klar; D L Heene
Journal:  Klin Wochenschr       Date:  1984-10-15

5.  Immunohistochemical study of fibronectin in human glioma and meningioma.

Authors:  N Kochi; E Tani; T Morimura; T Itagaki
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

6.  Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

Authors:  C Haglund; S Ylätupa; P Mertaniemi; P Partanen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Cellular fibronectin in serum and plasma: a potential new tumour marker?

Authors:  S Ylätupa; C Haglund; P Mertaniemi; E Vahtera; P Partanen
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.